Article: Genetics Institute seeks summary judgement against Amgen for EPO patent infringement. (erythropoietin)

GENETICS INSTITUTE SEEKS SUMMARY JUDGEMENT AGAINST

AMGEN FOR EPO PATENT INFRINGEMENTT

CAMBRIDGE, Mass., Feb. 4 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENI), has announced several developments in its legal dispute with Amgen, Inc., concerning patent rights to erythropoietin (EPO), a protein that controls the rate of red blood cell production in the human body.

Gabriel Schmergel, president and chief executive officer of Genetics Institute, said that the company has filed a Motion for Summary Judgement against Amgen in a suit now pending in the Federal District Court of Massachusetts. The suit charges Amgen with ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!